GlassScriptPhysician profile
Benjamin Quintana
NPI 1265522585
$151,486.56
in general payments reported to CMS, 2019-2025
24 companies · $3,362 in 2025
The $3,362 reported for 2025 was more than what 84% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $22K · 2021: $17K · 2022: $36K · 2023: $18K · 2024: $14K · 2025: $3,362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Food and Beverage: $4,008 · Travel and Lodging: $680 · Education: $24.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,588.75 |
| Food and Beverage | $4,007.86 |
| Travel and Lodging | $679.53 |
| Education | $24.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $44,323.22 | 2019-2024 | Farxiga, Brilinta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38,985.51 | 2019-2025 | Jardiance, Tradjenta, Glyxambi |
| Novo Nordisk INC | $36,834.17 | 2019-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $24,841.76 | 2019-2024 | Jardiance, Mounjaro, Trulicity |
| Dexcom, INC. | $1,791.39 | 2019 | |
| Medtronic, INC. | $1,298.93 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Biotronik INC. | $825.56 | 2025 | |
| Abbott Laboratories | $448.53 | 2019-2024 | Freestyle Libre 3 |
| Abbvie INC. | $348.95 | 2019 | |
| Medtronic Minimed, INC. | $282.07 | 2019-2020 | |
| Amgen INC. | $225.26 | 2020-2024 | Evenity |
| Janssen Pharmaceuticals, INC | $223.94 | 2019 | |
| Insulet Corporation | $213.41 | 2022-2025 | Omnipod |
| Tandem Diabetes Care, INC. | $188.93 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $164.80 | 2021-2023 | Recorlev |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sequel Med Tech, LLC | $133.54 | 2025 | Twiist |
| Opko Pharmaceuticals, LLC | $132.42 | 2021 | |
| Mannkind Corporation | $63.65 | 2022-2023 | Afrezza |
| Embecta Corp. | $48.12 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Sanofi-Aventis U.S. LLC | $37.36 | 2022 | |
| Becton, Dickinson and Company | $24.53 | 2022 | |
| Halozyme INC | $20.99 | 2023 | |
| Horizon Therapeutics Plc | $14.98 | 2022 | |
| Amryt Pharma Holdings LTD | $14.54 | 2023 | Mycapssa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Quintana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.